Sequoia Financial Advisors LLC Reduces Position in Pfizer Inc. $PFE

Sequoia Financial Advisors LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 332,178 shares of the biopharmaceutical company’s stock after selling 21,947 shares during the period. Sequoia Financial Advisors LLC’s holdings in Pfizer were worth $7,999,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Evolution Wealth Management Inc. boosted its holdings in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares during the period. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer in the fourth quarter valued at $26,000. Keb Asset Management LLC bought a new stake in shares of Pfizer in the 2nd quarter worth about $26,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Field & Main Bank bought a new position in shares of Pfizer during the 2nd quarter valued at approximately $27,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 0.1%

NYSE PFE opened at $27.69 on Friday. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $29.21. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company has a market capitalization of $157.82 billion, a PE ratio of 36.43, a P/E/G ratio of 1.86 and a beta of 0.34. The company has a fifty day moving average of $26.35 and a 200 day moving average of $26.37.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer’s dividend payout ratio is currently 226.32%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PFE. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a report on Tuesday, June 9th. BMO Capital Markets reduced their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. HSBC increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. decreased their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.